Adriamycin and Cis-Platinum as First-Line Treatment in Unresectable Locally Advanced or Metastatic Adult Soft-Tissue Sarcomas

2004 ◽  
Vol 27 (3) ◽  
pp. 307-311 ◽  
Author(s):  
Haralabos P. Kalofonos ◽  
Dimitrios Bafaloukos ◽  
Theodoros G. Kourelis ◽  
Michalis V. Karamouzis ◽  
Panagiotis Megas ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Locally Advanced ◽  
Soft Tissue Sarcomas ◽  
Line Treatment ◽  
First Line ◽  
First Line Treatment

Retrospective clinical analysis of MAID protocol as first-line treatment on 137 metastatic soft-tissue sarcomas patients

2012 ◽  
Vol 11 (2) ◽  
pp. 117-120 ◽  
Author(s):  
Kun Han ◽  
Yuanjue Sun ◽  
Jianjun Zhang ◽  
Lina Tang ◽  
Shui’er Zheng ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Soft Tissue Sarcomas ◽  
Clinical Analysis ◽  
Line Treatment ◽  
First Line ◽  
First Line Treatment

A phase II study of anlotinib in the first-line treatment of locally advanced or metastatic soft tissue sarcoma.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. e23531-e23531
Author(s):  
Xin Huang ◽  
Zhaoming Ye ◽  
Tao Li ◽  
Yongzhong Wei ◽  
Shoufeng Wang ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Disease Control ◽  
Interim Analysis ◽  
Locally Advanced ◽  
Line Treatment ◽  
First Line ◽  
Metastatic Soft Tissue Sarcoma ◽  
First Line Treatment

e23531 Background: Standard treatment for patients with unresectable locally advanced or metastatic soft-tissue sarcoma is chemotherapy based on anthracyclines, while the tolerance of chemotherapy is limited. We assessed if anlotinib, a multitarget tyrosine kinase inhibitor, is efficacy and safety for the first-line treatment of these patients. Methods: This is an open-label, single-arm, multicenter, phase II clinical trial (NCT03792542) including 44 planned subjects. Eligible patients were aged 18-70 years old, diagnosed with locally advanced or metastatic soft-tissue sarcoma and had at least one measurable lesion according to RECIST 1.1. Other inclusion criteria included ECOG PS 0̃2, chemotherapy and anti-angiogenesis treatment naïve. Patients were administrated 12mg anlotinib once daily for 14 days every 3 weeks until disease progression or unacceptable toxicity. The primary endpoint was progression-free survival (PFS). Safety assessment was done in patients who received at least one dose of anlotinib. Here we report the results of a planned interim analysis. Results: From April 2019 to December 2020, 29 patients (16 males and 13 females) were enrolled from 7 hospitals in China. The median age is 57 (range 23-69). Pathological types included liposarcoma (n = 8), undifferentiated pleomorphic sarcoma (n = 5), fibrosarcoma (n = 5), synovial sarcoma (n = 4), and others (n = 7). At the data cutoff date on December 31, 2020, the median duration of treatment was 5.3 months, and the median PFS was not reached. 26 patients were eligible for the evaluation of tumor response.1 achieved partial response (PR) and the objective response rate (ORR) was 3.85% (1/26). 24 had stale disease (SD) and the disease control rate (DCR) was 96.2% (25/26). The clinical benefit rate (CBR), defined as the proportion of patients who achieved durable disease control (CR/PR/SD) more than 4 and 6 months, were 65.4% (17/26) and 38.5% (10/26) respectively. Most adverse events (AE) were grade 1 or 2. The most common grade 3 AE was hypertension (17.2%). No grade 4 AEs or treatment related death occurred in this study through the last follow-up. Conclusions: This interim analysis showed anlotinib of promising efficacy and favorable tolerance in the first-line treatment of locally advanced or metastatic soft- tissue sarcoma. Clinical trial information: NCT03792542.

Sign in / Sign up

Export Citation Format

Share Document